New progress in AIDS vaccine research and development! Vaccines may usher in new opportunities
August 9, 2025
Source: drugdu
53
Recently, a research team including the AIDS Prevention and Control Center of the Chinese Center for Disease Control and Prevention completed the first phase I clinical trial of the Tiantan vaccinia vector HIV vaccine in China. This milestone progress has quickly ignited the development of biological vaccines.And market enthusiasm for related pharmaceutical sectors.
With its mature technical route, the vaccine has successfully obtained complete Phase I clinical trial data, laying a solid foundation for breakthroughs in AIDS vaccine research and development, marking an important progress in my country's vaccine innovation field and injecting strong momentum into the medical innovation track.
Against this backdrop, the pharmaceutical innovation sector continues to garner market attention, with positive factors accumulating. The Hang Seng Pharmaceutical ETF (159892) and the Biotech ETF (516500), which cover leading biopharmaceutical vaccine companies, are expected to capitalize on this wave of industry innovation and become a valuable tool for investors to capitalize on opportunities in the pharmaceutical innovation sector.
https://finance.eastmoney.com/a/202508053476345186.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Investigation raises concerns over tooth stem cell banking claims August 21, 2025
- Seniors Neglecting Steps To Protect Heart Health, Study Says August 21, 2025
- Pfizer’s $5.4 billion gamble fails August 21, 2025
- InnoCare Pharma’s new anticancer drug Mesutoclax completes first patient dosing in clinical trial August 21, 2025
- Novartis’ innovative drug Noradrena approved for IgA nephropathy in China August 21, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
